[Federal Register Volume 72, Number 19 (Tuesday, January 30, 2007)]
[Notices]
[Page 4298]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-1402]



[[Page 4298]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on November 17, 2006, 
Mallinckrodt Inc., 3600 North Second Street, St. Louis, Missouri 63147, 
made application by renewal to the Drug Enforcement Administration 
(DEA) to be registered as a bulk manufacturer of the basic classes of 
controlled substances listed in schedule I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Codeine-N-oxide (9053)......................  I
Difenoxin (9168)............................  I
Dihydromorphine (9145)......................  I
Morphine-N-oxide (9307).....................  I
Norlevorphanol (9634).......................  I
Normorphine (9313)..........................  I
Tetrahydrocannabinols (7370)................  I
Nabilone (7379).............................  II
Alfentanil (9737)...........................  II
Amphetamine (1100)..........................  II
Ecgonine (9180).............................  II
Codeine (9050)..............................  II
Dextropropoxyphene, bulk (9273).............  II
Dihydrocodeine (9120).......................  II
Diphenoxylate (9170)........................  II
Diprenorphine (9058)........................  II
Etorphine HCL (9059)........................  II
Fentanyl (9801).............................  II
Hydrocodone (9193)..........................  II
Hydromorphone (9150)........................  II
Levo-alphacetylmethadol (9648)..............  II
Levorphanol (9220)..........................  II
Meperidine (9230)...........................  II
Methadone (9250)............................  II
Methadone intermediate (9254)...............  II
Methamphetamine (1105)......................  II
Methylphenidate (1724)......................  II
Metopon (9260)..............................  II
Morphine (9300).............................  II
Opium extracts (9610).......................  II
Opium fluid extract (9620)..................  II
Opium tincture (9630).......................  II
Opium, granulated (9640)....................  II
Opium, powdered (9639)......................  II
Oxycodone (9143)............................  II
Oxymorphone (9652)..........................  II
Noroxymorphone (9668).......................  II
Phenazocine (9715)..........................  II
Alfentanil (9737)...........................  II
Remifentanil (9739).........................  II
Sufentanil (9740)...........................  II
Thebaine (9333).............................  II
------------------------------------------------------------------------

    The firm plans to manufacture the listed controlled substances for 
internal use and for sale to other companies.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration pursuant to 21 CFR 
1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative/ODL; or any being sent via express mail should be sent 
to DEA Headquarters, Attention: DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must 
be filed no later than April 2, 2007.

    Dated: January 23, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E7-1402 Filed 1-29-07; 8:45 am]
BILLING CODE 4410-09-P